A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
a study on Prostate Cancer
Castration-Resistant Prostatic Neoplasms Prostatic Neoplasms Prostatic Neoplasms, Castration-Resistant Cetrelimab 480 mg Apalutamide 240 mg
Lead Scientist at UCSF
- Rahul Aggarwal
I am a Medical Oncologist within the Division of Hematology/Oncology at the University of California San Francisco. My clinical practice focuses on patients with advanced solid tumor malignancies with a particular emphasis on genitourinary malignancies including prostate, kidney, bladder, and testicular cancer. I serve as the Co-Leader for the GU Medical Oncology program at UCSF.
- accepting new patients
- Start Date
- Completion Date
- Janssen Research & Development, LLC
- To learn how to participate in this trial please click here.
- Phase 1
- Study Type
- Last Updated